Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02930902 | Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05711433 | Risk Factors for Postoperative Pancreatic Fistula Following Non-traumatic Pancreatic Surgery. Retrospective Observational Study. | completed | — | 347 | Zagazig UniversityOTHER_GOV | 0 | Feb 3, 2023 |
| clinicaltrials |
| NCT03977272 | Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer | completed | Phase 2 | 110 | Zhejiang UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT04476082 | Nutrition in Gastrointestinal Tumors(NutriGIT) | completed | — | 66 | University Medicine GreifswaldOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 117 | AmMax Bio, Inc.INDUSTRY | 6 | Jan 20, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02948309 | Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer(MISTRAL) | completed | Phase 3 | 290 | Karolinska University HospitalOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT01774643 | A Study of Pancreatic Cancer in Xenografts From Liver Metastases | completed | — | 31 | University Health Network, TorontoOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | completed | Phase 2 | 24 | Translational Genomics Research InstituteOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT01939665 | PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma(PANFIRE) | completed | Phase 1 / Phase 2 | 50 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02791503 | CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy(CROSSFIRE) | completed | N/A | 74 | Dr. M.R. MeijerinkOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT03817866 | Chromogranin A as Blood Marker in Cancer Patients | completed | — | 175 | Brahms AGINDUSTRY | 2 | Dec 20, 2022 | clinicaltrials |
| NCT02873598 | A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer | completed | Phase 1 | 14 | University of Colorado, DenverOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT04080024 | A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer(SPAGOPIX-01) | completed | Phase 1 | 14 | Spago Nanomedical ABINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine(ALPACA) | completed | Phase 2 | 325 | AIO-Studien-gGmbHOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02810652 | Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection | completed | N/A | 160 | Massachusetts General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT03798769 | Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX | completed | N/A | 60 | Massachusetts General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02784353 | Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy(PReHeBP) | completed | N/A | 158 | Asan Medical CenterOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05616403 | Textbook Outcome as a Composite Outcome Measure in Laparoscopic Pancreaticoduodenectomy | completed | — | 1,029 | Tongji HospitalOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT05226572 | Repeated EUS-guided Fine Needle Biopsy of Pancreatic Masses After Non-diagnostic or Inconclusive Results(REuBio) | completed | — | 462 | University of BolognaOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02428270 | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05266300 | Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. | completed | — | 722 | University of Southern DenmarkOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01926197 | Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer | completed | Phase 3 | 27 | Stanford UniversityOTHER | 2 | Oct 28, 2022 | clinicaltrials |
| NCT02830620 | Study at the Man of the Profile of Chimiokines in the Anorexia Bound to the Cancerous Cachexy(CHIMIOKINES) | completed | N/A | 40 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC(Trybeca-1) | completed | Phase 3 | 512 | ERYtech PharmaINDUSTRY | 3 | Oct 18, 2022 | clinicaltrials |
| NCT05305001 | Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico | completed | — | 107 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02489422 | Programs To Support You During Chemotherapy(PRO-YOU) | completed | N/A | 44 | Wake Forest University Health SciencesOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02173353 | Feasibility of Using Ultrasound to Track Respiration Motion | completed | — | 15 | Medical College of WisconsinOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04747600 | Outcomes of Surgical Resection of Pancreatic Cystic Neoplasms Based on the European Expert Consensus Statement: A Prospective Observational Study. | completed | — | 63 | Zagazig UniversityOTHER_GOV | 0 | Oct 10, 2022 | clinicaltrials |
| NCT01662609 | Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer | completed | — | 90 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT03883919 | Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy | completed | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT01845805 | Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine) | completed | Phase 2 | 49 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02651987 | Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg(CLARINET FORTE) | completed | Phase 2 | 99 | IpsenINDUSTRY | 10 | Oct 3, 2022 | clinicaltrials |
| NCT05547074 | A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma | completed | — | 302 | Zhejiang UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT02349867 | Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer | completed | Phase 1 | 23 | Virginia Commonwealth UniversityOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT03158779 | Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 45 | Istituto Clinico HumanitasOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT00981162 | Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride | completed | Phase 1 | 12 | Roswell Park Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02588443 | Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma | completed | Phase 1 | 19 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT02394535 | Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT03662204 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors | completed | — | 5,133 | Exact Sciences CorporationINDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT04483349 | Assessment of What Patients and Healthcare Providers Value | completed | — | 397 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04334239 | Effectiveness of Care in Certified Cancer Centres in Germany(WiZen) | completed | — | 670,000 | Technische Universität DresdenOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT01547260 | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer(LENAGEM) | completed | Phase 1 / Phase 2 | 34 | Maria LiljeforsOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT03257150 | A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer | completed | N/A | 12 | University Health Network, TorontoOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT04769414 | Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN) | completed | Phase 2 | 48 | Menoufia UniversityOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT01229943 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | completed | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
| NCT03614910 | Ablation of Unresectable Locally Advanced Pancreatic Cancer With Irreversible Electroporation (IRE) System | completed | — | 30 | Holy Name Medical Center, Inc.OTHER | 1 | Aug 3, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 9, 2023source: clinicaltrials